Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout

NCT02500641 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

196

Enrollment

INDUSTRY

Sponsor class

Conditions

Gout

Interventions

DRUG: Febuxostat 80/120mg/day
DRUG: Allopurinol 100 up to 600mg/day
DRUG: Colchicine
DRUG: Naproxen
DRUG: Omeprazole

Sponsor

Menarini International Operations Luxembourg SA